(linezolid)

Prescribing Information
Download Prescribing Information

HIGHLIGHTS OF PRESCRIBING INFORMATION

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ZYVOX safely and effectively. See full prescribing information for ZYVOX.

ZYVOX® (linezolid) injection, for intravenous use
ZYVOX® (linezolid) tablets, for oral use
ZYVOX® (linezolid) for oral suspension
Initial U.S. Approval: 2000

RECENT MAJOR CHANGES

Warnings and Precautions, Serotonin Syndrome (5.3)

6/2026

INDICATIONS AND USAGE

ZYVOX is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia (1.1); Community-acquired pneumonia (1.2); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis (1.3); Uncomplicated skin and skin structure infections (1.4); Vancomycin-resistant Enterococcus faecium infections. (1.5)


Limitations of Use (1.6):

•
ZYVOX is not indicated for the treatment of Gram-negative infections.
•
The safety and efficacy of ZYVOX formulations given for longer than 28 days have not been evaluated in controlled clinical trials.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX formulations and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.7)

DOSAGE AND ADMINISTRATION

Dosage, Route, and Frequency of Administration (2)

Infection (2)

Pediatric Patients
(Birth through 11 years of Age) (2)

Adults and Adolescents
(12 years and Older) (2)

Duration
(days) (2)

Nosocomial pneumonia (2)

10 mg/kg intravenous or oral every 8 hours (2)

600 mg intravenous or oral every 12 hours (2)

10 to 14 (2)

Community-acquired pneumonia, including concurrent bacteremia (2)

Complicated skin and skin structure infections (2)

Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia (2)

10 mg/kg intravenous or oral every 8 hours (2)

600 mg intravenous or oral every 12 hours (2)

14 to 28 (2)

Uncomplicated skin and skin structure infections (2)

less than 5 yrs: 10 mg/kg oral every 8 hours
5–11 yrs: 10 mg/kg oral every 12 hours (2)

Adults: 400 mg oral every 12 hours
Adolescents: 600 mg oral every 12 hours (2)

10 to 14 (2)

DOSAGE FORMS AND STRENGTHS

•
Injection: 200 mg/100 mL (2 mg/mL) and 600 mg/300 mL (2 mg/mL) linezolid. (3)
•
Tablet: 600 mg linezolid. (3)
•
For oral suspension: 100 mg of linezolid per each 5 mL. (3)

CONTRAINDICATIONS

•
Known hypersensitivity to linezolid or any of the other product components. (4.1)
•
Patients taking any monoamine oxidase inhibitors (MAOI) or within two weeks of taking an MAOI. (4.2)

WARNINGS AND PRECAUTIONS

•
Myelosuppression: Monitor complete blood counts weekly. Thrombocytopenia has been reported more often in patients with severe renal and in patients with moderate to severe hepatic impairment. Consider discontinuation in patients who develop or have worsening myelosuppression. (5.1)
•
Peripheral and Optic Neuropathy: Reported primarily in patients treated for longer than 28 days. If patients experience symptoms of visual impairment, prompt ophthalmic evaluation is recommended. (5.2)
•
Serotonin Syndrome: Monitor patients taking ZYVOX concomitantly with serotonergic agents for signs of serotonin syndrome. If signs or symptoms of serotonin syndrome occur, consider discontinuing ZYVOX and/or concomitant serotonergic agents. (5.3)
•
A mortality imbalance was seen in an investigational study in linezolid-treated patients with catheter-related bloodstream infections. (5.4)
•
Clostridioides difficile-Associated Diarrhea: Evaluate if diarrhea occurs. (5.5)
•
Potential interactions producing elevation of blood pressure: monitor blood pressure. (5.6)
•
Rhabdomyolysis: If signs or symptoms of rhabdomyolysis are observed, discontinue ZYVOX and initiate appropriate therapy. (5.9)
•
Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (5.10)
•
Hyponatremia and/or Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): Monitor serum sodium levels regularly in patients at risk of hyponatremia and/or SIADH. (5.11)
•
Phenylketonuria: ZYVOX for Oral Suspension contains phenylalanine which can be harmful to patients with phenylketonuria. (5.12)

ADVERSE REACTIONS

Most common adverse reactions (>5% of adult and/or pediatric patients treated with ZYVOX) include diarrhea, vomiting, headache, nausea, and anemia. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Monoamine oxidase inhibitors and potential for interaction with adrenergic and serotonergic agents. (4.2, 5.3, 5.6, 7, 12.3)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 6/2026

Additional Resources

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine or vaccine.

Speak with a Pfizer Medical Information Professional regarding your Pfizer medicine or vaccine inquiry.

Available 9AM-5PM ET Monday to Friday; excluding holidays.

 

Submit a medical question for a Pfizer medicine or a vaccine. 

The submission will be reviewed during our standard business hours.

To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this medication, click the link below to submit your information: 
Pfizer Safety Reporting Site

*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.

If you cannot use the above website to report an adverse event related to a Pfizer medication, please call (800) 438-1985.

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or by calling (800) 332-1088.